Dixon Technologies has received significant government backing with HSBC upgrading the stock to 'buy' from 'hold' and raising the price target to ₹16,000 from ₹12,000, implying 17% upside potential from Wednesday's closing levels. This follows Macquarie's earlier upgrade to ₹16,000 from ₹15,000 on Wednesday. The upgrades come after the Union Cabinet approved the ₹62,500 crore mobile manufacturing scheme to strengthen India's electronics ecosystem. According to HSBC, the scheme will improve Dixon's mobile phone margins by 30 basis points and has increased the target price-to-earnings multiple to 48x. Macquarie expects the Vivo joint venture to triple Dixon's earnings per share by FY2029, with 28%/43% revenue/EPS CAGRs over FY26-29.
The Indian government granted approval to Dixon Tech's long-pending joint venture with Chinese phone maker Vivo, marking the single biggest factor for the stock since its disappointing Q4 FY26 results in May. The JV will be in a 51:49 ratio between Dixon Technologies (majority stake) and Vivo under Press Note 3 (PN3) norms, with the JV acting as a major contract manufacturer producing smartphones and electronic devices for Vivo and potentially other brands. Nomura estimated that the JV could potentially ramp up volumes to 60 million handsets over the next few years, as 70% share in Vivo will top up 33 million units already sold by Dixon Tech in FY26. CEO Atul Lall had previously told investors in May that Dixon Tech was deeply engaged with the government, stating they were "very close" to approval, and that claim now has government paperwork behind it.
Dixon Tech shares surged as much as 7% to their day's high of ₹14,680 on the BSE on Thursday after the Union Cabinet approved the ₹1.27 lakh crore second phase of the India Semiconductor Mission and a ₹62,500 crore Mobile Phone Manufacturing Scheme. Among 33 analysts covering the stock, 24 have 'buy' ratings, 3 have 'hold' ratings, and 6 have 'sell' ratings. The positive momentum reflects growing confidence in the company's positioning in India's expanding electronics manufacturing sector. Dixon Technologies shares climbed 7.4% to ₹14,656 in early trade on Thursday, emerging as the top gainer on the BSE Midcap index, lifting the company's market capitalisation to around ₹83,770 crore. The stock has delivered 27% gains in the last 3 months and is up 19% so far in 2026, though it has declined 10% in the last 12 months.
Despite the positive developments, analysts remain divided on Dixon's competitive positioning. Nomura expects margins to expand from 3.3% in FY27 to 4.2% in FY28, with benefits starting to show from H2 FY27, driven by backward integration and increased domestic value addition. However, Jefferies maintains a Hold rating, flagging concerns about increased competition compared to 2021 levels. The company's Production Linked Incentive (PLI) incentives of around ₹350 crore in FY26 are expiring this financial year, with nothing confirmed to replace them. As Dixon Tech has historically functioned primarily as an EMS assembler, it relies heavily on importing high-value internal parts, mainly from China and Taiwan, though the government is pressing for domestic value addition under PLI 2.0.
Market analysts and brokerage firms have identified five high-conviction trading ideas for the upcoming session, focusing on sectors including biotechnology, auto finance, chemicals, sugar, and industrial manufacturing. According to reports from NDTV Profit, the top picks for Monday, July 13 include Biocon, TSF Investments, Neogen Chemicals, Triveni Engineering & Industries, and DOMS Industries. These recommendations come from multiple market experts and research analysts who have identified technical strength and momentum across these sectors. The latest brokerage calls also include Divi's Labs, Dixon Technologies, Nuvoco Vistas, Adani Ports, and Sheela Foam across various sectors.
